Insights & news

Belgium - Consumer Rights Association Files Excessive Pricing Competition Complaint Against Leadiant Over Price for Treatment of Rare Disease

  • 09/04/2019
  • Articles

Consumer rights association “Test Aankoop”/ “Test-Achats” (“TA”) piled further pressure on pharmaceutical firm Leadiant when it announced on 5 April 2019 that it had submitted a complaint to the Belgian Competition Authority challenging Leadiant’s allegedly excessive prices for chenodeoxycholic acid Leadiant (“CDCA”) (see attached press release).  CDCA is indicated for the treatment of patients afflicted with cerebrotendinous xanthomatosis, a rare metabolic disorder (“CTX”). CDCA was designated as an orphan medicine in December 2014.
 
Unusually, CDCA is highly similar to a medicine with the same active substance which has been indicated for many years for the treatment of cholesterol gallstones. According to TA, back in 2005 this treatment of an adult patient cost EUR 427 per annum. By contrast, the treatment of CTX in reliance on CDCA carries a cost of EUR 153,300 per patient per year. TA maintains that this difference cannot be explained by Leadiant’s research and development activities, which it dismisses as insignificant, or other justifications.
 
The case is understood to be under review by the Dutch competition authority as well. Additionally, it has prompted Vytenis Andriukaitis, the Commissioner responsible for health and food safety, to promise closer scrutiny of the rules governing orphan medicines in the pending assessment of the regulatory framework (see, Van Bael & Bellis Life Sciences Newsflash of 11 February 2019).

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 04/06/2020
    • Articles

    Europe - Four-Country Inclusive Vaccine Alliance In Quest for Covid-19 Vaccine

    In a letter to Parliament and a press release (see, attachments), the Dutch Minister for Public Health, Wellbeing and Sports, Hugo de Jonge, revealed on 3 June 2020 an initiative of Italy, France, Germany and The Netherlands to work together to secure a Covid-19 vaccine for “the European Union and other countries”.   According to the Minister, the “Inclusive Vaccine Alliance” (IVA) is in talks with several pharmaceutical companies regarding promising ventures and in the process hopes to establish a European manufacturing base for the vaccine. The IVA’s ultimate goal is to create a medicine that is “accessible, available and affordable”.   Other countries will be given the opportunity to join the IVA which is also in contact with the European Commission.

    Read more
    • 03/06/2020
    • Articles

    European Commission Publishes Roadmap Towards Pharmaceutical Strategy for Europe

    The European Commission (the Commission) published on 2 June 2020 its roadmap towards a Pharmaceutical Strategy for Europe (PSE) which it plans to publish in the fourth quarter of 2020 (see, attachment). The roadmap defines the steps which the Commission will take prior to adopting the PSE and the data which it will assemble to inform its PSE. While the Commission will consult a range of stakeholders, it has already announced a public consultation which will run until 7 July 2020.

    Read more
    • 02/06/2020
    • Articles

    Italian Competition Authority Approves Scheme for Distribution of Surgical Masks

    On 1 June 2020, the Italian competition authority (“L’Autorità Garante della Concorrenza e del Mercato”) authorised a scheme that would allow disposable surgical masks to be distributed and sold in pharmacies and health product retail outlets (see, attached press release). It did so at the request of the two principal Italian associations of pharmaceutical wholesalers. Under the scheme, the wholesalers and associations of pharmacists and health product retailers acquire the masks in a joint procurement procedure. The masks are then allocated among the wholesalers at a uniform price per unit that was agreed upon with the suppliers. The scheme will last until 30 June 2020. The competition authority approved the scheme because it solves an urgent and wide-ranging health problem and is limited in time. It thus applied for the first time the principles of its guidance of 22 April 2020 regarding cooperation agreements designed to ensure the distribution of scarce essential goods and services, including health products and food. The competition authority’s approach is in line with the views expressed by the European Commission and competition authorities around Europe to address the problems resulting from the Covid-19 pandemic (see e.g., Van Bael & Bellis Life Sciences News Alert of 9 April 2020 and of 26 May 2020). Not coincidentally, the competition authority indicates that it obtained counsel from the European Commission.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *